The Exhaled Nitric Oxide Detectors market growth is led by North America, which dominates with 40% market share, driven by advanced healthcare infrastructure, high adoption of precision diagnostics, and robust R&D investments. Regulatory policies promoting early detection of respiratory diseases, such as asthma and COPD, further accelerate demand. In Europe, the 30% share reflects strong ecosystem maturity, with Germany and the UK leveraging stringent air quality regulations and public-private partnerships to expand diagnostic accessibility. Asia Pacific emerges as the fastest-growing region, projected at 15% CAGR, fueled by rising asthma prevalence, government initiatives to modernize healthcare in India and China, and improving diagnostic infrastructure. Latin America (10%) and the Middle East & Africa (5%) show potential, with Latin America benefiting from growing private-sector investments and the Middle East leveraging infrastructure development in the GCC to enhance respiratory disease management.